Lagier J. C., Million M., Cortaredona Sébastien, Delorme L., Colson P., Fournier P. E., Brouqui P., Raoult D., Parola P. (2022). Outcomes of 2111 COVID-19 hospitalized patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France, 2020 : a monocentric retrospective analysis. Therapeutics and Clinical Risk Management, 18, p. [15 p.].
Titre du document
Outcomes of 2111 COVID-19 hospitalized patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France, 2020 : a monocentric retrospective analysis
Année de publication
2022
Auteurs
Lagier J. C., Million M., Cortaredona Sébastien, Delorme L., Colson P., Fournier P. E., Brouqui P., Raoult D., Parola P.
Source
Therapeutics and Clinical Risk Management, 2022,
18, p. [15 p.]
Objectives: We evaluated the 6-week mortality of SARS-CoV-2 hospitalized patients treated using a standardized protocol in 2020 in Marseille, France. Methods: A retrospective monocentric cohort study was conducted in the standard hospital wards at the Institut Hospitalo-Universitaire Mediterranee Infection, between March and December 2020 in adults with SARS-CoV-2 PCR-proven infection. Results: Of the 2111 hospitalized patients (median age, 67 [IQR 55-79] years; 1154 [54.7%] men), 271 were transferred to the intensive care unit (12.8%) and 239 died (11.3%; the mean age of patients who died was 81.2 (+/- 9.9)). Treatment with hydroxy-chloroquine plus azithromycin (HCQ-AZ), used in 1270 patients, was an independent protective factor against death (0.68 [0.52 - 0.88]). This effect was consistent for all subgroups of age, comorbidities, severity of the disease and comedications with zinc or corticosteroids. Zinc was independently protective against death (0.39 [0.23 - 0.67]), in a subgroup analysis of patients treated with HCQ-AZ without dexamethasone. The use of high-flow oxygen therapy in elderly patients who were not eligible for intensive care unit transfer saved 19 patients (33.9%). Conclusions: In our 2020 cohort, treating COVID-19 with HCQ-AZ was associated with lower mortality. These results need to be analyzed in the context of academic discussions about observational studies versus randomized clinical trials. More data will deserve to be analyzed in the SARS-Cov 2 variants, vaccination and post-vaccination era.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
FRANCE ; MARSEILLE
Localisation
Fonds IRD [F B010085291]
Identifiant IRD
fdi:010085291
